Our study showed that WISP3 suppressed the progression of HCC by negative regulation of β‐catenin/TCF/LEF signalling, providing WISP3 as a potential therapeutic candidate for HCC. The gene discussed is HNF4A; the disease is hepatocellular carcinoma.